Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology

Marelize Swart, Wesley M. Stansberry, Victoria M. Pratt, Elizabeth B. Medeiros, Patrick J. Kiel, Fei Shen, Bryan Schneider, Todd Skaar

Research output: Contribution to journalArticle

Abstract

The Clinical Laboratory Improvement Amendments of 1988 require that pharmacogenetic genotyping methods need to be established according to technical standards and laboratory practice guidelines before testing can be offered to patients. Testing methods for variants in ABCB1, CBR3, COMT, CYP3A7, C8ORF34, FCGR2A, FCGR3A, HAS3, NT5C2, NUDT15, SBF2, SEMA3C, SLC16A5, SLC28A3, SOD2, TLR4, and TPMT were validated in a Clinical Laboratory Improvement Amendments–accredited laboratory. Because no known reference materials were available, existing DNA samples were used for the analytical validation studies. Pharmacogenetic testing methods developed here were shown to be accurate and 100% analytically sensitive and specific. Other Clinical Laboratory Improvement Amendments–accredited laboratories interested in offering pharmacogenetic testing for these genetic variants, related to genotype-guided therapy for oncology, could use these publicly available samples as reference materials when developing and validating new genetic tests or refining current assays.

Original languageEnglish (US)
Pages (from-to)491-502
Number of pages12
JournalJournal of Molecular Diagnostics
Volume21
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Genotype
Therapeutics
Validation Studies
Pharmacogenetics
Practice Guidelines
DNA
Pharmacogenomic Testing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology. / Swart, Marelize; Stansberry, Wesley M.; Pratt, Victoria M.; Medeiros, Elizabeth B.; Kiel, Patrick J.; Shen, Fei; Schneider, Bryan; Skaar, Todd.

In: Journal of Molecular Diagnostics, Vol. 21, No. 3, 01.05.2019, p. 491-502.

Research output: Contribution to journalArticle

Swart, Marelize ; Stansberry, Wesley M. ; Pratt, Victoria M. ; Medeiros, Elizabeth B. ; Kiel, Patrick J. ; Shen, Fei ; Schneider, Bryan ; Skaar, Todd. / Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology. In: Journal of Molecular Diagnostics. 2019 ; Vol. 21, No. 3. pp. 491-502.
@article{a4c740515610466790aa465e2cb8a974,
title = "Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology",
abstract = "The Clinical Laboratory Improvement Amendments of 1988 require that pharmacogenetic genotyping methods need to be established according to technical standards and laboratory practice guidelines before testing can be offered to patients. Testing methods for variants in ABCB1, CBR3, COMT, CYP3A7, C8ORF34, FCGR2A, FCGR3A, HAS3, NT5C2, NUDT15, SBF2, SEMA3C, SLC16A5, SLC28A3, SOD2, TLR4, and TPMT were validated in a Clinical Laboratory Improvement Amendments–accredited laboratory. Because no known reference materials were available, existing DNA samples were used for the analytical validation studies. Pharmacogenetic testing methods developed here were shown to be accurate and 100{\%} analytically sensitive and specific. Other Clinical Laboratory Improvement Amendments–accredited laboratories interested in offering pharmacogenetic testing for these genetic variants, related to genotype-guided therapy for oncology, could use these publicly available samples as reference materials when developing and validating new genetic tests or refining current assays.",
author = "Marelize Swart and Stansberry, {Wesley M.} and Pratt, {Victoria M.} and Medeiros, {Elizabeth B.} and Kiel, {Patrick J.} and Fei Shen and Bryan Schneider and Todd Skaar",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.jmoldx.2019.01.009",
language = "English (US)",
volume = "21",
pages = "491--502",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "3",

}

TY - JOUR

T1 - Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology

AU - Swart, Marelize

AU - Stansberry, Wesley M.

AU - Pratt, Victoria M.

AU - Medeiros, Elizabeth B.

AU - Kiel, Patrick J.

AU - Shen, Fei

AU - Schneider, Bryan

AU - Skaar, Todd

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The Clinical Laboratory Improvement Amendments of 1988 require that pharmacogenetic genotyping methods need to be established according to technical standards and laboratory practice guidelines before testing can be offered to patients. Testing methods for variants in ABCB1, CBR3, COMT, CYP3A7, C8ORF34, FCGR2A, FCGR3A, HAS3, NT5C2, NUDT15, SBF2, SEMA3C, SLC16A5, SLC28A3, SOD2, TLR4, and TPMT were validated in a Clinical Laboratory Improvement Amendments–accredited laboratory. Because no known reference materials were available, existing DNA samples were used for the analytical validation studies. Pharmacogenetic testing methods developed here were shown to be accurate and 100% analytically sensitive and specific. Other Clinical Laboratory Improvement Amendments–accredited laboratories interested in offering pharmacogenetic testing for these genetic variants, related to genotype-guided therapy for oncology, could use these publicly available samples as reference materials when developing and validating new genetic tests or refining current assays.

AB - The Clinical Laboratory Improvement Amendments of 1988 require that pharmacogenetic genotyping methods need to be established according to technical standards and laboratory practice guidelines before testing can be offered to patients. Testing methods for variants in ABCB1, CBR3, COMT, CYP3A7, C8ORF34, FCGR2A, FCGR3A, HAS3, NT5C2, NUDT15, SBF2, SEMA3C, SLC16A5, SLC28A3, SOD2, TLR4, and TPMT were validated in a Clinical Laboratory Improvement Amendments–accredited laboratory. Because no known reference materials were available, existing DNA samples were used for the analytical validation studies. Pharmacogenetic testing methods developed here were shown to be accurate and 100% analytically sensitive and specific. Other Clinical Laboratory Improvement Amendments–accredited laboratories interested in offering pharmacogenetic testing for these genetic variants, related to genotype-guided therapy for oncology, could use these publicly available samples as reference materials when developing and validating new genetic tests or refining current assays.

UR - http://www.scopus.com/inward/record.url?scp=85064558971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064558971&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2019.01.009

DO - 10.1016/j.jmoldx.2019.01.009

M3 - Article

C2 - 30794985

AN - SCOPUS:85064558971

VL - 21

SP - 491

EP - 502

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 3

ER -